Enveda Closes $311M Series E to Fuel Ambitions
Enveda has closed a $311 million Series E round, one of the year's larger biotech financings, to fund its stated ambition of becoming a "household name" in medicine.
Topic
Drug Discovery
Topic
Drug Discovery
Parabilis Aims for IPO After $800M Raise to Attack 'Undruggable' Targets
Parabilis has raised $800 million and is pursuing an IPO to fund drugs against "undruggable" targets, BioPharma Dive reports, tes…